These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20122099)

  • 1. Introduction: The challenge of developing oversight approaches to nanobiotechnology.
    Paradise J; Wolf SM; Kuzma J; Ramachandran G; Kokkoli E
    J Law Med Ethics; 2009; 37(4):543-5. PubMed ID: 20122099
    [No Abstract]   [Full Text] [Related]  

  • 2. Developing U.S. oversight strategies for nanobiotechnology: learning from past oversight experiences.
    Paradise J; Wolf SM; Kuzma J; Kuzhabekova A; Tisdale AW; Kokkoli E; Ramachandran G
    J Law Med Ethics; 2009; 37(4):688-705. PubMed ID: 20122110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating oversight systems for emerging technologies: a case study of genetically engineered organisms.
    Kuzma J; Najmaie P; Larson J
    J Law Med Ethics; 2009; 37(4):546-86. PubMed ID: 20122100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Governance of nanotechnology and nanomaterials: principles, regulation, and renegotiating the social contract.
    Kimbrell GA
    J Law Med Ethics; 2009; 37(4):706-23. PubMed ID: 20122111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commentary: Emerging technologies oversight: research, regulation, and commercialization.
    Johnson R
    J Law Med Ethics; 2009; 37(4):587-93. PubMed ID: 20122101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commentary: Is it possible to determine the extent to which informational asymmetries and prejudice bias responses?
    Hurley T
    J Law Med Ethics; 2009; 37(4):594-7. PubMed ID: 20122102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy oversight: lessons for nanobiotechnology.
    Wolf SM; Gupta R; Kohlhepp P
    J Law Med Ethics; 2009; 37(4):659-84. PubMed ID: 20122108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commentary: Who's afraid of the RAC? Lessons from the oversight of controversial science.
    Kahn JP
    J Law Med Ethics; 2009; 37(4):685-7. PubMed ID: 20122109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk communication for nanobiotechnology: to whom, about what, and why?
    Priest SH
    J Law Med Ethics; 2009; 37(4):759-69. PubMed ID: 20122115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulating small things: genes, gametes and nanotechnology.
    Bennett B
    J Law Med; 2007 Aug; 15(1):153-60. PubMed ID: 17902497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using expert elicitation to prioritize resource allocation for risk identification for nanosilver.
    Fauss E; Gorman ME; Swami N
    J Law Med Ethics; 2009; 37(4):770-80. PubMed ID: 20122116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What does the history of technology regulation teach us about nano oversight?
    Marchant GE; Sylvester DJ; Abbott KW
    J Law Med Ethics; 2009; 37(4):724-31. PubMed ID: 20122112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulating biotechnology: a rational-political model of policy development.
    Wiktorowicz M; Deber R
    Health Policy; 1997 May; 40(2):115-38. PubMed ID: 10167067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating oversight of human drugs and medical devices: a case study of the FDA and implications for nanobiotechnology.
    Paradise J; Tisdale AW; Hall RF; Kokkoli E
    J Law Med Ethics; 2009; 37(4):598-624. PubMed ID: 20122103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UK government caught in GM dilemma.
    Mitchell P
    Nat Biotechnol; 2003 Sep; 21(9):957. PubMed ID: 12949540
    [No Abstract]   [Full Text] [Related]  

  • 16. Science, ethics, and the "problems" of governing nanotechnologies.
    Hogle LF
    J Law Med Ethics; 2009; 37(4):749-58. PubMed ID: 20122114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Problem formulation and option assessment (PFOA) linking governance and environmental risk assessment for technologies: a methodology for problem analysis of nanotechnologies and genetically engineered organisms.
    Nelson KC; Andow DA; Banker MJ
    J Law Med Ethics; 2009; 37(4):732-48. PubMed ID: 20122113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: introduction to nanotechnology: potential applications in physical medicine and rehabilitation.
    Agoramoorthy G; Chakraborty C
    Am J Phys Med Rehabil; 2007 Dec; 86(12):1031-2; author reply 1032. PubMed ID: 18090446
    [No Abstract]   [Full Text] [Related]  

  • 19. Review of the OSHA framework for oversight of occupational environments.
    Choi JY; Ramachandran G
    J Law Med Ethics; 2009; 37(4):633-50. PubMed ID: 20122106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanotechnology. EPA ponders voluntary nanotechnology regulations.
    Service RF
    Science; 2005 Jul; 309(5731):36. PubMed ID: 15994499
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.